Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Krystal Biotech (KRYS)
NASDAQ:KRYS
Holding KRYS?
Track your performance easily
KRYS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$107.50 - $219.34
Previous Close$160.83
Volume898.32K
Average Volume (3M)231.81K
Market Cap
$4.63B
Enterprise Value$4.04B
Total Cash (Recent Filing)$588.32M
Total Debt (Recent Filing)$7.48M
Price to Earnings (P/E)91.0
Beta1.32
Next Earnings
Mar 03, 2025EPS Estimate
$1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.77
Shares Outstanding28,760,548
10 Day Avg. Volume391,644
30 Day Avg. Volume231,809
Standard Deviation0.15
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)5.35
Price to Sales (P/S)19.15
Price to Cash Flow (P/CF)19.70
P/FCF Ratio20.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue16.75
Enterprise Value/Gross Profit84.96
Enterprise Value/Ebitda24.90
Forecast
1Y Price Target
$210.43Price Target Upside27.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Krystal Biotech News
PremiumCompany Announcements
Krystal Biotech Reports Positive Results for KYANITE-1 Study
PremiumCompany Announcements
Krystal Biotech Reports Promising Results for Genetic Medicine
PremiumCompany Announcements
Krystal Biotech Reports Strong Q3 2024 PerformanceBulls Say, Bears Say
Bulls Say
Clinical EfficacyThe overall response rate in target lung lesions specifically was 36%, with three partial responses and one complete response, and disease control rate of 82%.
Clinical Safety And TolerabilityThe safety profile of ‘707 in the NSCLC population is strong, with most adverse events being mild to moderate and no grade 4+ adverse events recorded.
Platform PotentialInitial KB707 data supports the safe readministration of Krystal’s inhaled HSV-1 genetic platform, which has positive implications for KB408 in AATD and KB407 in cystic fibrosis.
Bears Say
Management GuidanceManagement guided to a continued downward trend on compliance.
Market PerformanceThe maturing of the Vyjuvek launch is pressuring the stock.
Treatment Effectiveness‘707 responses in NSCLC look comparable with common treatment options but are slightly lacking compared to some targeted therapies.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
KRYS FAQ
What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was $107.50 and its highest was $219.34 in the past 12 months.
What is Krystal Biotech’s market cap?
Currently, no data Available
When is Krystal Biotech’s upcoming earnings report date?
Krystal Biotech’s upcoming earnings report date is Mar 03, 2025 which is in 72 days.
How were Krystal Biotech’s earnings last quarter?
Krystal Biotech released its earnings results on Nov 04, 2024. The company reported $0.91 earnings per share for the quarter, missing the consensus estimate of $0.993 by -$0.083.
Is Krystal Biotech overvalued?
According to Wall Street analysts Krystal Biotech’s price is currently Undervalued.
Does Krystal Biotech pay dividends?
Krystal Biotech does not currently pay dividends.
What is Krystal Biotech’s EPS estimate?
Krystal Biotech’s EPS estimate is $1.18.
How many shares outstanding does Krystal Biotech have?
Krystal Biotech has 28,760,548 shares outstanding.
What happened to Krystal Biotech’s price movement after its last earnings report?
Krystal Biotech reported an EPS of $0.91 in its last earnings report, missing expectations of $0.993. Following the earnings report the stock price went down -3.141%.
Which hedge fund is a major shareholder of Krystal Biotech?
Among the largest hedge funds holding Krystal Biotech’s share is Woodline Partners LP. It holds Krystal Biotech’s shares valued at 33M.
---
Krystal Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$210.43 (27.66% Upside)
$210.43 (27.66% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 78.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $106.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.00%
12-Months-Change
Fundamentals
Return on Equity
6.38%
Trailing 12-Months
Asset Growth
24.29%
Trailing 12-Months
Company Description
Krystal Biotech
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.
---
KRYS Company Deck
---
KRYS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong financial performance with significant revenue growth and profitability. International expansion plans and pipeline advancements were well-received, though seasonal disruptions and litigation expenses posed challenges.Read More>---
KRYS Stock 12 Month Forecast
Average Price Target
$210.43
▲(27.66% Upside)
Technical Analysis
Best Analysts Covering KRYS
1 Year
1 Year Success Rate
13/15 ratings generated profit
1 Year Average Return
+45.93%
reiterated a buy rating 2 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +45.93% per trade.
---